The dilemma: Does tissue expression of cathepsin D reflect tumor malignancy? the question: Does the assay truly mirror cathepsin D mis-function in the tumor?

Cancer Biomarkers

Volumn 7, Issue 1, 2010, Pages 47-64

  Nicotra, Giuseppina ^a   Castino, Roberta ^a   Follo, Carlo ^a   Peracchio, Claudia ^a   Valente, Guido ^a   Isidoro, Ciro ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

cell death; Lysosome; metastasis; prognosis; proteolysis; tumor marker

Indexed keywords

CATHEPSIN D;

APOPTOSIS; BLADDER CANCER; BRAIN TUMOR; BREAST CANCER; CANCER GROWTH; COLORECTAL CANCER; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENETIC TRANSCRIPTION; GLIOBLASTOMA; HEAD AND NECK CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNORADIOMETRIC ASSAY; LUNG CANCER; MELANOMA; OVARY CANCER; PANCREAS CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METABOLISM; REVIEW; STOMACH CANCER;

BREAST NEOPLASMS; CATHEPSIN D; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; ENDOSOMES; ENZYME PRECURSORS; FEMALE; GOLGI APPARATUS; HEAD AND NECK NEOPLASMS; HUMANS; LUNG NEOPLASMS; LYSOSOMES; MALE; MELANOMA; NEOPLASMS; NERVOUS SYSTEM NEOPLASMS; OVARIAN NEOPLASMS; PANCREATIC NEOPLASMS; PROSTATIC NEOPLASMS; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 78149332780     PISSN: 15740153     EISSN: None     Source Type: Journal    
DOI: 10.3233/CBM-2010-0143     Document Type: Review

References (205)

1. A.J. Barrett and D. Cathepsin, Purification of isoenzymes from human and chicken liver, Biochem J 117 (1970), 601-607.
2. V.Cavaillès, P.Augereau andH.Rochefort, CathepsinD gene is controlled by a mixed promoter, and estrogens stimulate only TATA-dependent transcription in breast cancer cells, Proc Natl Acad Sci USA 90 (1993), 203-207.
3. P. Augereau, F. Miralles, V. Cavaillès, C. Gaudelet, M. Parker and H. Rochefort, Characterization of the proximal estrogen-responsive element of human cathepsin D gene, Mol En-docrinol 8 (1994), 693-703.
4. G.S. Wu, P. Saftig, C. Peters and W.S. El-Deiry, Potential role for cathepsin D in p53-dependent tumor suppression and chemosensitivity, Oncogene 16 (1998), 2177-2183.
5. V. Sagulenko, D. Muth, E. Sagulenko, T. Paffhausen, M. Schwab and F. Westermann, Cathepsin D protects human neuroblastoma cells from doxorubicin-induced cell death, Carcinogenesis 29 (2008), 1869-1877.
6. K. von Figura and A. Hasilik, Lysosomal enzymes and their receptors, Annu Rev Biochem 55 (1986), 167-193.
7. F. Capony, T. Braulke, C. Rougeot, S. Roux, P. Montcourrier and H. Rochefort, Specific mannose-6-phosphate receptor-independent sorting of pro-cathepsin D in breast cancer cells, Exp Cell Res 215 (1994), 154-163.
8. F. Dittmer, E.J. Ulbrich, A. Hafner, W. Schmahl, T. Meister, R. Pohlmann and K. von Figura, Alternative mechanisms for trafficking of lysosomal enzymes in mannose 6-phosphate receptor-deficient mice are cell type-specific, J Cell Sci 112 (1999), 1591-1597.
9. R. Castino and C.Isidoro, Transport of solubile lysosomal hydrolases from the Golgi complex to lysosomes, in: The Golgi Apparatus, A. Mironov and M. Pavelka, eds, Springer-WienNewYork, 2008, pp. 402-413.
10. T. Kobayashi, K. Honke, S. Gasa, T. Fujii, S. Maguchi, T. Miyazaki and A. Makita, Proteolytic processing sites producing the mature form of human cathepsin D, Int J Biochem 24 (1992), 1487-1491.
11. C. Follo, R. Castino, G. Nicotra, NF. Trincheri and C. Isidoro, Folding, activity and targeting of mutated human cathepsin D that cannot be processed into the double-chain form, Int J Biochem Cell Biol 39 (2007), 638-649.
12. F. Capony, C. Rougeot, P. Montcourrier, V. Cavailles, G. Salazar and H. Rochefort, Increased secretion, altered processing, and glycosylation of pro-cathepsin D in human mammary cancer cells, Cancer Res 15 (1989), 3904-3909.
13. C. Isidoro, F.M. Baccino and A. Hasilik, Mis-sorting of pro-cathepsin D in metastogenic tumor cells is not due to impaired synthesis ofthe phosphomannosyl signal, Int J Cancer 70 (1997), 561-566.
14. C. Isidoro, M. Démoz, D. De Stefanis, F.M. Baccino, A. Hasilik and G. Bonelli, Differential targeting and processing of procathepsin D in normal and transformed murine 3T3 fibroblasts, Int J Cancer 70 (1997), 310-314.
15. L. Emert-Sedlak, S. Shangary, A. Rabinovitz, M.B. Miranda, S.M. Delach and D.E. Johnson, Involvement of cathepsin D in chemotherapy-induced cytochrome c release, caspase activation, and cell death, Mol Cancer Ther 4 (2005), 733-742.
16. N. Bidère, H.K. Lorenzo, S. Carmona, M. Laforge, F. Harper, C. Dumont and A. Senik, Cathepsin D triggers Bax activation, resulting in selective apoptosis-inducing factor (AIF) relocation in T lymphocytes entering the early commitment phase to apoptosis, J Biol Chem 278 (2003), 31401-31411.
17. N.F. Trincheri, G. Nicotra, C. Follo, R. Castino and C. Isidoro, Resveratrol induces cell death in colorectal cancer cells by a novel pathway involving lysosomal cathepsin D, Carcinogenesis 28 (2007), 922-931.
18. R. Castino, N. Bellio, G. Nicotra, C. Follo, N.F. Trincheri and C. Isidoro, Cathepsin D-Bax death pathway in oxidative stressed neuroblastoma cells, Free Radic Biol Med 42(2007), 1305-1316.
19. R. Castino, C. Peracchio, A. Salini, G. Nicotra, N.F. Trincheri, M. Démoz, G. Valente and C. Isidoro, Chemotherapy drug response in ovarian cancer cells strictly depends on a cathepsin D-Bax activation loop, J Cell Mol Med 13 (2009), 1096-1109.
20. A. Rodŕiguez, P. Webster, J. Ortego andN.W. Andrews, Lyso-somes behave as Ca2+-regulated exocytic vesicles in fibrob-lasts and epithelial cells, J Cell Biol 137 (1997), 93-104.
21. A. Dragonetti, M. Baldassarre, R. Castino, M. Démoz, A. Luini, R. Buccione and C. Isidoro, The lysosomal protease cathepsin D is efficiently sorted to and secreted from regulated secretory compartments in the rat basophilic/mast cell line RBL, J Cell Sci 113 (2000), 3289-3298.
22. M. Lkhider, R. Castino, E. Bouguyon, C. Isidoro and M. Ollivier-Bousquet, Cathepsin D released by lactating rat mammary epithelial cells is involved in prolactin cleavage under physiological conditions, J Cell Sci 117 (2004), 5155-5164.
23. R. Carini, R. Castino, M.G. De Cesaris, R. Splendore, M. Démoz, E. Albano and C. Isidoro, Preconditioning-induced cytoprotection in hepatocytes requires Ca(2+)dependent ex-ocytosis of lysosomes, J Cell Sci 117 (2004), 1065-1077.
24. R. Castino, M. Démoz and C. Isidoro, Destination 'lyso-some': a target organelle for tumour cell killing? J Mol Recognit 16 (2003), 337-348.
25. T. Nomura and N. Katunuma, Involvement of cathepsins in the invasion, metastasis and proliferation of cancer cells, J Med Invest 52 (2005), 1-9.
26. E. Liaudet-Coopman, M. Beaujouin, D. Derocq, M. Garcia, M. Glondu-Lassis, V. Laurent-Matha, C. Prébois, H. Rochefort and F. Mignon, Cathepsin D: newly discovered functions of a long-standing aspartic protease in cancer and apoptosis, Cancer Lett 237 (2006), 167-179.
27. M. Fusek and V. Vetvicka, Dual role of cathepsin D: ligand and protease, Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 149 (2005), 43-50.
28. A. Minarowska, M. Gacko, A.Karwowska and Ł.Minarows-ki, Human cathepsin D, Folia Histochem Cytobiol 46 (2008), 23-38.
29. P. Benes, V. Vetvicka and M. Fusek, Cathepsin D-many functions of one aspartic protease, Crit Rev Oncol Hematol 68 (2008), 12-28.
30. C. Isidoro, M. Demoz, D. De Stefanis, F.M. Baccino and G. Monelli, Synthesis,maturation and extracellular release of procathepsin D as influenced by cell proliferation or transformation, Int J Cancer 63 (1995), 866-871.
31. M. Garcia, D. Derocq, P. Pujol and H. Rochefort, Overex-pression of transfected cathepsin D in transformed cells increases their malignant phenotype and metastatic potency, Oncogene 12 (1990), 1809-1814.
32. E. Liaudet, D. Derocq, H. Rochefort and M. Garcia, Trans-fected cathepsin D stimulates high density cancer cell growth by inactivating secreted growth inhibitors, Cell Growth Differ 6 (1995), 1045-1052.
33. G. Berchem, M. Glondu, M. Gleizes, J.P. Brouillet, F. Vi-gnon, M. Garcia and E. Liaudet-Coopman, Cathepsin-D affects multiple tumor progression steps in vivo: proliferation, angiogenesis andapoptosis, Oncogene21(2002), 5951-5955.
34. S.S. Ohri, A. Vashishta, M. Proctor, M. Fusek and V. Vetvic-ka, The propeptide of cathepsin D increases proliferation, invasion and metastasis of breast cancer cells, Int J Oncol 32 (2008), 491-498.
35. T.D. Lockwood and W.T. Shier, Regulation of acid proteases during growth, quiescence and starvation in normal and transformed cells, Nature 267 (1977), 252-254.
36. H.O. Byun, N.K. Han, H.J. Lee, K.B. Kim, Y.G. Ko, G. Yoon, Y.S. Lee, S.I. Hong and J.S. Lee, Cathepsin D and eukary-otic translation elongation factor 1 as promising markers of cellular senescence, Cancer Res 69 (2009), 4638-4647.
37. L.P. Deiss, H. Galinka, H. Berissi, O. Cohen and A. Kim-chi, Cathepsin D protease mediates programmed cell death induced by interferon-gamma, Fas/APO-1 and TNF-alpha, EMBO J 15 (1996), 3861-3870.
38. M. Démoz, R. Castino, P. Cesaro, F.M. Baccino, G. Monelli and C. Isidoro, Endosomal-lysosomal proteolysis mediates death signalling by TNFalpha, not by etoposide, in L929 fibrosarcoma cells: evidence for an active role of cathepsin D, Biol Chem 383 (2002), 1237-1248.
39. A.C. Johansson, H. Steen, K. Ollinger and K. Roberg, Cathepsin D mediates cytochrome c release and caspase activation in human fibroblast apoptosis induced by stau-rosporine, Cell Death Differ 10 (2003), 1253-1259.
40. M. Beaujouin, S. Baghdiguian, M. Glondu-Lassis, G. Berchem and E. Liaudet-Coopman, Overexpression of both catalytically active and-inactive cathepsin D by cancer cells enhances apoptosis-dependent chemo-sensitivity, Oncogene 25 (2006), 1967-1973.
41. K. Lorenzo, P. Ton, J.L. Clark, S. Coulibaly and L. Mach, Invasive properties of murine squamous carcinoma cells: secretion of matrix-degrading cathepsins is attributable to a deficiency in the mannose 6-phosphate/insulin- like growth factor II receptor, Cancer Res 60 (2000), 4070-4076.
42. O.C. Probst, V. Puxbaum, B. Svoboda, V. Leksa, H. Stockinger, M. Mikula, W. Mikulits and L. Mach, The man-nose 6-phosphate/insulin-like growth factor II receptor restricts the tumourigenicity and invasiveness of squamous cell carcinoma cells, Int J Cancer 124 (2009), 2559-2567.
43. M. Mathieu, F. Vignon, F. Capony and H. Rochefort, Estra-diol down-regulates the mannose-6-phosphate/insulin-like growth factor-II receptor gene and induces cathepsin-D in breast cancer cells: a receptor saturation mechanism to increase the secretion of lysosomal proenzymes, Mol En-docrinol 5 (1991), 815-822.
44. F. Galtier-Dereure, F. Capony, T. Maudelonde and H. Rochefort, Estradiol stimulates cell growth and secretion of procathepsin D and a 120-kilodalton protein in the human ovarian cancer cell line BG-1, J Clin Endocrinol Metab 75 (1992), 1497-1502.
45. F. Vignon, F. Capony, M. Chambon, G. Freiss, M. Garcia and H. Rochefort, Autocrine growth stimulation of the MCF 7 breast cancer cells by the estrogen-regulated 52 K protein, Endocrinology 118 (1986), 1537-1545. (Pubitemid 16078532)
46. M. Mathieu, H. Rochefort, B. Barenton, C. Prebois and F. Vignon, Interactions of cathepsin-D and insulin-like growth factor-II (IGF-II) on the IGF-II/mannose-6-phosphate receptor in human breast cancer cells and possible consequences on mitogenic activity of IGF-II, Mol Endocrinol 4 (1990), 1327-1335.
47. V. Vetvicka, J. Vektvicková and M. Fusek, Effect of human procathepsin D on proliferation of human cell lines, Cancer Lett 79 (1994), 131-135.
48. V. Vetvicka, J.Vetvickova and M.Fusek, Effect ofprocathep-sin D and its activation peptide on prostate cancer cells, Cancer Lett 129 (1998), 55-59.
49. M. Glondu, P. Coopman, V. Laurent-Matha, M. Garcia, H. Rochefort and E. Liaudet-Coopman, A mutated cathepsin-D devoid of its catalytic activity stimulates the growth ofcancer cells, Oncogene 20 (2001), 6920-6929.
50. M. Fusek and V. Vetvicka, Mitogenic function of human procathepsin D: the role of the propeptide, Biochem J 303 (1994), 775-780.
51. V. Vetvicka, J. Vetvickova, I. Hilgert, Z. Voburka and M. Fusek, Analysis of the interaction of procathepsin D activation peptide with breast cancer cells, Int J Cancer 73 (1997), 403-409.
52. V. Vetvicka, J. Vetvickova and P. Benes, Role of enzymati-cally inactive procathepsin D in lung cancer, Anticancer Res 24 (2004), 2739-2743.
53. S. Wittlin, J. Rösel, F. Hofmann and D.R. Stover, Mechanisms and kinetics of procathepsin D activation, Eur J Biochem 265 (1999), 384-393.
54. J.R. Griffiths, Are cancer cells acidic? Br JCancer64(1991), 425-427.
55. M. Stubbs, P.M. McSheehy, J.R. Griffiths and C.L. Bashford, Causes and consequences of tumour acidity and implications for treatment, Mol Med Today 6 (2000), 15-19.
56. N. Heylen, L.M. Vincent, V. Devos, V. Dubois, C. Remacle and A. Trouet, Fibroblasts capture cathepsin D secreted by breast cancer cells: possible role in the regulation of the invasive process, Int J Oncol 20 (2002), 761-767.
57. Z.Khalkhali-Ellis and M.J. Hendrix, Elucidating the function of secreted maspin: inhibiting cathepsin D-mediated matrix degradation, Cancer Res 67 (2007), 3535-3539.
58. P. Briozzo, J. Badet, F. Capony, I. Pieri, P. Montcourrier, D. Barritault and H. Rochefort, MCF7 mammary cancer cells respond to bFGF and internalize it following its release from extracellular matrix: a permissive role of cathepsin D, Exp Cell Res 194 (1991), 252-259.
59. M.J. Humphries and S.R. Ayad, Stimulation of DNA synthesis by cathepsin D digests of fibronectin, Nature 305 (1983), 811-813.
60. G. Leto, N. Gebbia, L. Rausa and F.M. Tumminello, Cathep-sin D in the malignant progression of neoplastic diseases (review), Anticancer Res 12 (1992), 235-240.
61. H. Rochefort, M. Garcia, M. Glondu, V. Laurent, E. Liaudet, JM. Rey and P. Roger, Cathepsin D in breast cancer: mechanisms and clinical applications, a 1999 overview, Clin Chim Acta 291 (2000), 157-170.
62. G. Leto, F.M. Tumminello, M. Crescimanno, C. Flandina and N. Gebbia, Cathepsin D expression levels in nongynecolog-ical solid tumors: clinical and therapeutic implications, Clin Exp Metastasis 21 (2004), 91-106.
63. D. Parham, J.N. Whitaker and C.W. Berard, Cellular distribution of cathepsin D in childhood tumors, Arch Pathol Lab Med 109 (1985), 250-255.
64. W.A. Reid, M.J. Valler and J. Kay, Immunolocalization of cathepsin D in normal and neoplastic human tissues, J Clin Pathol 39 (1986), 1323-1330.
65. D.K. Robson, J.W. Ironside, W.A. Reid and P.R. Bogue, Im-munolocalization of cathepsin D in the human central nervous system and central nervous system neoplasms, Neuropathol Appl Neurobiol 16 (1990), 39-44.
66. M.J. Newbould, A.M. Kelsey, J.C. Arango, J.W. Ironside and J. Birch, The choroid plexus carcinomas of childhood: histopathology, immunocytochemistry and clinicopatholog-ical correlations, Histopathology 26 (1995), 137-143.
67. M. Warich, P. von Bossanyi and K. Dietzmann, Expression of cathepsin D in human astrocytic neoplasias, Gen Diagn Pathol 141 (1995), 93-96.
68. E.A. Castilla, R.A. Prayson, C.M. Abramovich and M.L. Cohen, Immunohistochemical expression of cathepsin D in meningiomas, Am J Clin Pathol 119 (2003), 123-128.
69. D.S. Tews and A. Nissen, Expression of adhesion factors and degrading proteins in primary and secondary glioblastomas and their precursor tumors, Invasion Metastasis 18 (1998-1999), 271-284.
70. M. Sivaparvathi, R. Sawaya, S.K. Chintala, Y. Go, Z.L. Gokaslan and J.S. Rao, Expression of cathepsin D during the progression of human gliomas, Neurosci Lett 208 (1996), 171-174. (Pubitemid 26140149)
71. D.S. Tews, Adhesive and invasive features in gliomas, Pathol Res Pract 196 (2000), 701-711.
72. M.E. Fukuda, Y. Iwadate, T. Machida, T. Hiwasa, Y. Nimura, Y. Nagai, M. Takiguchi, H. Tanzawa, A. Yamaura and N. Seki, Cathepsin D is a potential serum marker for poor prognosis in glioma patients, Cancer Res 65 (2005), 5190-5194.
73. R. Castino, D. Pace, M. Démoz, M. Gargiulo, C. Ariatta, E. Reiteri and C. Isidoro, Lysosomal proteases as potential targets for the induction of apoptotic cell death in human neuroblastomas, Int J Cancer 97 (2002), 775-779.
74. S. Marsigliante, L. Biscozzo, L. Resta, G. Leo, A. Mottaghi, E. Maiorano, G. Colucci and C. Storelli, Immunohistochem-ical and immunoradiometric evaluations of total cathepsin D in human larynx, Eur J Cancer B Oral Oncol 30B (1994), 51-55.
75. N. Vigneswaran, S. Müller, P. DeRose and C. Cohen, Cathepsin-D and tumor associated antigen DF3 in salivary gland neoplasia. Differential diagnostic and prognostic applications, Pathol Res Pract 190 (1994), 1174-1184.
76. J. Kos, A. Smid, M. Krasovec, B. Svetic, B. Lenarcic, I. Vrhovec, J. Skrk and V. Turk, Lysosomal proteases cathep-sins D, B, H, L and their inhibitors stefins A and B in head and neck cancer, Biol Chem Hoppe Seyler 376 (1995), 401-405.
77. R. Zeillinger, S. Eder, C. Schneeberger, R. Ullrich, P. Speiser andH.Swoboda, CathepsinDand PAI-1 expressioninhuman head and neck cancer, Anticancer Res 16 (1996), 449-453. (Pubitemid 26128506)
78. P. Strojan, M. Budihna, L. Smid, I.Vrhovec and J. Skrk, Cathepsin D in tissue and serum of patients with squamous cell carcinoma of the head and neck, Cancer Lett 130 (1998), 49-56.
79. A. Goussia, E. Ioachim, D. Peschos, D. Assimakopoulos, T. Vougiouklakis, A. Skevas and N. Agnantis, Immunohisto-chemical expression of cathepsin D in laryngeal epithelial lesions: correlation with CD44 expression, p53 and Rb status and proliferation associated indices, Anticancer Res 19 (1999), 3055-3060.
80. R. Gandour-Edwards, B. Trock and P.J. Donald, Predictive value of cathepsin-D for cervical lymph node metastasis in head and neck squamous cell carcinoma, Head Neck 21 (1999), 718-722.
81. N. Vigneswaran, W. Zhao, A. Dassanayake, S. Muller, D.M. Miller and W. Zacharias, Variable expression of cathepsin B and D correlates with highly invasive and metastatic pheno-type of oral cancer, Hum Pathol 31 (2000), 931-937.
82. G. Kawasaki, Y. Kato and A. Mizuno, Cathepsin expression in oral squamous cell carcinoma: relationship with clinico-pathologic factors, Oral Surg Oral Med Oral Pathol Oral Radiol Endod 93 (2002), 446-454. (Pubitemid 41124667)
83. J. Breton, M.C. Gage, A.W. Hay, J.N. Keen, C.P. Wild, C. Donnellan, J.B. Findlay and L.J. Hardie, Proteomic screening of a cell line model of esophageal carcinogenesis identifies cathepsin D and aldo-keto reductase 1C2 and 1B10 dys-regulation in Barrett's esophagus and esophageal adenocar-cinoma, J Proteome Res 7 (2008), 1953-1962.
84. M. Ikeguchi, T. Sakatani, T. Ueta, K. Fukuda, S. Oka, K. Hisamitsu, K. Yamaguchi, S. Tsujitani and N. Kaibara, Correlation between cathepsin D expression and p53 protein nuclear accumulation in oesophageal squamous cell carcinoma, J Clin Pathol 55 (2002), 121-126. (Pubitemid 34123913)
85. I. Lentari, I. Segas and D.Kandiloros, The importance of cathepsin's-D tissular detection in laryngeal squamous cell carcinoma, Acta Otorhinolaryngol Belg 56 (2002), 383-389.
86. M. Maurizi, G. Almadori, G. Cadoni, G. Scambia, F. Otta-viani, G. Ferrandina, G. Paludetti, G. D'Abramo and S. Man-cuso, Cathepsin D concentration in primary laryngeal cancer: correlation with clinico-pathological parameters, EGFR status and prognosis, Int J Cancer 69 (1996), 105-109.
87. S. Seiwerth, N. Stambuk, P. Konjevoda, N. Masić, A. Vasilj, M. Bura, I. Klapan, S. Manojlović and D. Danić, Immuno-histochemical analysis and prognostic value of cathepsin D determination in laryngeal squamous cell carcinoma, J Chem Inf Comput Sci 40 (2000), 545-549.
88. A.C. Lazaris, I. Lendari, N. Kavantzas, D. Kandiloros, G. Adamopoulos and P. Davaris, Correlation of tumor markers p53, bcl-2 and cathepsin-D with clinicopathologic features and disease-free survival in laryngeal squamous cell carcinoma, Pathol Int 50 (2000), 717-724.
89. A.L. Cheng, W.G. Huang, Z.C. Chen, P.F. Zhang, M.Y. Li, F. Li, J.L. Li, C. Li, H. Yi, F. Peng, C.J. Duan and Z.Q. Xiao, Identificating cathepsin D as a biomarker for differentiation and prognosis of nasopharyngeal carcinoma by laser capture microdissection and proteomic analysis, J Proteome Res 7 (2008), 2415-2426.
90. L. Chyczewski, A. Płoński, E. Chyczewska, M. Furman, H. Ostrowska, J. Nikliński and M. Kozłowski, Activity and tissue localization of cathepsin D in non small cell lung cancer, Rocz Akad Med Bialymst 42 (1999), 217-229.
91. P. Ledakis, W.T. Tester, N. Rosenberg, D. Romero-Fischmann, I. Daskal and T.T. Lah, Cathepsins D, B, and L in malignant human lung tissue, Clin Cancer Res 2 (1996), 561-568.
92. A. Sloman, F. D'Amico and S.A. Yousem, Immunohisto-chemical markers of prolonged survival in small cell carcinoma of the lung. An immunohistochemical study, Arch Pathol Lab Med 120 (1996), 465-472.
93. M. Higashiyama, O. Doi, K. Kodama, H. Yokouchi, T. Ka-sugai and S. Ishiguro, Influence of cathepsin D expression in lung adenocarcinoma on prognosis: possibile importance of its expression in tumor cells and stromal cells, and its intra-cellular polarization in tumor cells, J Surg Oncol 65 (1997), 10-19.
94. A. Woźniak, T. Drewa, M. Rozwodowska, G. Drewa, W. Lambrecht and I. Wiśniewska, Activity of some lysosomal enzymes in serum and in tumors of patients with squamous cell lung carcinoma, Neoplasma 49 (2002), 10-15.
95. G. Fontanini, S. Vignati, D. Bigini, G.R. Merlo, A. Ribecchi-ni, C.A. Angeletti, F. Basolo, R. Pingitore and G. Bevilacqua, Humannon-small cell lung cancer: p53 protein accumulation is an early event and persists during metastatic progression, J Pathol 174 (1994), 23-31.
96. S.M. Thorpe, H. Rochefort, M. Garcia, G. Freiss, I.J. Chris-tensen, S.Khalaf, F. Paolucci, B. Pau, B.B. Rasmussen and C. Rose, Association between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer, Cancer Res 49 (1989), 6008-6014.
97. B. Westley and H. Rochefort, A secreted glycoprotein induced by estrogen in human breast cancer cell lines, Cell 20 (1980), 353-362. (Pubitemid 10117751)
98. B.R. Westley and F.E. May, Oestrogen regulates cathepsin D mRNA levels in oestrogen responsive human breast cancer cells, Nucleic Acids Res 15 (1987), 3773-3786.
99. H. Rochefort, P. Augereau, P. Briozzo, F. Capony, V. Cavailles, G. Freiss, M. Garcia, T. Maudelonde, M. Morisset and F. Vignon, Structure, function, regulation and clinical significance of the 52K pro-cathepsin D secreted by breast cancer cells, Biochimie 70 (1988), 943-949
100. L.B. Riley, M.K. Lange, R.J. Browne, P.J. Cochrane, I.J. Choi, B. Davis, S. Arcona and J.A. Alhadeff, Analysis of cathepsin D in human breast cancer: usefulness of the processed 31 kDa active form of the enzyme as a prognostic indicator in node-negative and node-positive patients, Breast Cancer Res Treat 60 (2000), 173-179.
101. F. Spyratos, T. Maudelonde, J.P. Brouillet, M. Brunet, A. Defrenne, C. Andrieu, K. Hacene, A. Desplaces, J. Rouëssé and H. Rochefort, Cathepsin D: an independent prognostic factor for metastasis of breast cancer, Lancet 2 (1989), 1115-1118.
102. M.J. Duffy, J.P. Brouillet, D. Reilly, E. McDermott, N. O'Higgins, J.J. Fennelly, T. Maudelonde and H. Rochefort, Cathepsin D concentration in breast cancer cytosols: correlation with biochemical, histological, and clinical findings, Clin Chem 37 (1991), 101-104.
103. J.A. Foekens, M.P. Look, J. Bolt-de Vries, M.E. Meijer-van Gelder, W.L. van Putten and J.G. Klijn, Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810 patients, Br J Cancer 79 (1999), 300-307.
104. A. Scorilas, T. Trangas, J. Yotis, C. Pateras and M. Tal-ieri, Determination of c-myc amplification and overexpres-sion in breast cancer patients: evaluation of its prognostic value against c-erbB-2, cathepsin-D and clinicopathological characteristics using univariate and multivariate analysis, Br J Cancer 81 (1999), 1385-1391.
105. A. Scorilas, J. Yotis, C. Pateras, T. Trangas and M. Talieri, Predictive valueof c-erbB-2 and cathepsin-D for Greekbreast cancer patients using univariate and multivariate analysis, Clin Cancer Res 5 (1999), 815-821.
106. A.M. Billgren, L.E. Rutqvist, H. Johansson, T. Hägerström and L. Skoog, The role of cathepsin D and PAI-1 in primary invasive breast cancer as prognosticators and predictors of treatment benefit with adjuvant tamoxifen, Eur J Cancer 36 (2000), 1374-1380.
107. U.J. Göhring, A. Scharl, U. Thelen, A. Ahr and G. Crombach, Comparative prognostic value of Cathepsin D and uroki-nase plasminogen activator, detected by immunohistochem-istry, in primary breast carcinoma, Anticancer Res 16 (1996), 1011-1018.
108. J.H. Winstanley, S.J. Leinster, T.G. Cooke, B.R. Westley, A.M. Platt-Higgins and P.S.Rudland, Prognosticsignificance of cathepsin-D in patients with breast cancer, Br J Cancer 67 (1993), 767-772.
109. S. Veneroni, M.G. Daidone, G. Di Fronzo, V. Cappelletti, D. Amadori, A. Riccobon, A. Paradiso, M. Correale and R. Silvestrini, Quantitative immunohistochemical determination of cathepsin-D and its relation with other variables, Breast Cancer Res Treat 26 (1993), 7-13.
110. D.W. Visscher, F. Sarkar, P. LoRusso, W. Sakr, S. Ottosen, S. Wykes and J.D. Crissman, Immunohistologic evaluation of invasion-associated proteases in breast carcinoma, Mod Pathol 6 (1993), 302-306.
111. M. Markićević, A. Petrović, K. Kanjer, Z. Nesković-Konstantinović and D. Nikolić- Vukosavujević, Estrogen-regulated cut-off values of pS2 and cathepsin D expression in breast carcinomas, Adv Exp Med Biol 617 (2008), 341-348.
112. D. Nikolić-Vukosavljević, M. Markićević, G. Grujić-Adanja, A. Petrović, K. Kanjer and Z. Nesković- Konstantinović, Cathepsin D-related disease-free interval in pT1 primary breast carcinomas: a pilot study, Clin Exp Metastasis 22 (2005), 363-368.
113. J. Rodŕiguez, J. Vázquez, M.D. Corte, M. Lamelas, M. Bongera, M.G. Corte, A. Alvarez, M. Allende, L. Gonzalez, M. Sánchez, M. Vijande, J. Garcia Muñiz and F. Vi-zoso, Clinical significance of cathepsin D concentration in tumor cytosol of primary breast cancer, Int J Biol Markers 20 (2005), 103-111.
114. A.K. Tandon, G.M. Clark, G.C. Chamness, J.M. Chirgwin and W.L. McGuire, Cathepsin D and prognosis in breast cancer, N Engl J Med 322 (1990), 297-302.
115. M. Garćia, P. Augereau, P. Briozzo, F. Capony, V. Cavailles, G. Freiss, T. Maudelonde, P. Montcourrier, F. Vignon and H. Rochefort, Regulation, clinical and biological significance of cathepsin D in breast cancer, Rev Esp Fisiol 46 (1990), 39-41.
116. T.E. Kute, Z.M. Shao, N.K. Sugg, R.T. Long, G.B. Russell and L.D. Case, Cathepsin D as a prognostic indicator for node-negative breast cancer patients using both immunoas-says and enzymatic assays, Cancer Res 52 (1992), 5198-5203.
117. T.E. Kute, J. Grøndahl-Hansen, S.M. Shao, R. Long, G. Russell and N. Brünner, Low cathepsin D and low plasminogen activator type 1 inhibitor in tumor cytosols defines a group of node negative breast cancer patients with low risk of recurrence, Breast Cancer Res Treat 47 (1998), 9-16.
118. J.A.Foekens, W.L. van Putten, H.Portengen, H.Y.deKoning, B. Thirion, J. Alexieva-Figusch and J.G. Klijn, Prognostic value of PS2 and cathepsin D in 710 human primary breast tumors: multivariate analysis, J Clin Oncol 11 (1993), 899-908.
119. J.J. Isola, Immunohistochemical demonstration of androgen receptor in breast cancer and its relationship to other prognostic factors, J Pathol 170 (1993), 31-35.
120. T.T. Lah, M. Cercek, A. Blejec, J. Kos, E. Gorodetsky, R. Somers and I. Daskal, Cathepsin B, a prognostic indicator in lymph node-negative breast carcinoma patients: comparison with cathepsin D, cathepsin L, and other clinical indicators, Clin Cancer Res 6 (2000), 578-584.
121. T.T. Lah, E. Kalman, D. Najjar, E. Gorodetsky, P. Brennan, R. Somers and I. Daskal, Cells producing cathepsins D, B, and L in human breast carcinoma and their association with prognosis, Hum Pathol 31 (2000), 149-160.
122. N. Harbeck, U. Alt, U. Berger, R. Kates, A. Krüger, C. Thomssen, F. Jänicke, H. Graeff and M. Schmit, Long-term follow-up confirms prognostic impact of PAI-1 and cathepsin D and L in primary breast cancer, Int J Biol Markers 15 (2000), 79-83.
123. Z. Gaci, M.H. Bouin-Pineau, M. Gaci, A. Daban, P. Ingrand and T. Métayé, Prognostic impact of cathepsin D and c-erbB-2 oncoprotein in a subgroup of node-negative breast cancer patients with low histological grade tumors, Int J Oncol 18 (2001), 793-800.
124. Y. Niu, X. Fu, A. Lv, Y. Fan and Y. Wang, Potential markers predicting distant metastasis in axillary node-negative breast carcinoma, Int J Cancer 98 (2002), 754-760.
125. R. Seshadri, D.J. Horsfall, F. Firgaira, K. McCaul, V. Setlur, A.H. Chalmers, R. Yeo, D. Ingram, H. Dawkins and R. Hah-nel, The relative prognostic significance of total cathepsin D and HER-2/neu oncogene amplification in breast cancer, The South Australian Breast Cancer Study Group, Int J Cancer 56 (1994), 61-65.
126. P.L. Kandalaft, K.L. Chang, C.W. Ahn, S.T. Traweek, P. Mehta and H. Battifora, Prognostic significance of immuno-histochemical analysis of cathepsin D in low-stage breast cancer, Cancer 71 (1993), 2756-2763.
127. C. Charpin, S. Garcia, C. Bouvier, F. Martini, M. Lavaut, C. Allasia, P. Bonnier and L. Andrac, Cathepsin D detected by automated and quantitative immunohistochemistry in breast carcinomas: correlation with overall and disease free survival, J Clin Pathol 50 (1997), 586-590. (Pubitemid 27359517)
128. A. Scorilas, J. Yotis, D. Gouriotis, A. Keramopoulos, K. Ampela, T. Trangas and M. Talieri, Cathepsin-D and c-erb-B 2 have an additive prognostic value for breast cancer patients, Anticancer Res 13 (1993), 1895-1900.
129. P. Eng Tan, C.C. Benz, C. Dollbaum, D.H. 2nd Moore, S.M. Edgerton, D.T. Zava and A.D. Thor, Prognostic value of Cathepsin D expression in breast cancer: immunohistochem-ical assessment and correlation with radiometric assay, Ann Oncol 5 (1994), 329-336.
130. A. Lösch, C. Tempfer, P. Kohlberger, E.A. Joura, M. Denk, B. Zajic, G, Breitenecker and C. Kainz, Prognostic value of cathepsin D expression and association with histomorpho-logical subtypes in breast cancer, Br J Cancer 78 (1998), 205-209.
131. T. Jahkola, T. Toivonen, K. von Smitten, I. Virtanen, V.M. Wasenius and C. Blomqvist, Cathepsin-D, urokinase plas-minogen activator and type-1 plasminogen activator inhibitor in early breast cancer: an immunohistochemical study of prognostic value and relations totenascin-C and other factors, Br J Cancer 80 (1999), 167-174.
132. E. Ioachim, E. Tsanou, E. Briasoulis, Ch. Batsis, V. Kar-avasilis, A. Charchanti, N. Pavlidis, N.J. Agnantis, Clinico-pathological study of the expression of hsp27, pS2, cathep-sin D and metallothionein in primary invasive breast cancer, Breast 12 (2003), 111-119.
133. B. Têtu, J. Brisson, H. Lapointe, C.S. Wang, P. Bernard and C. Blanchette, Cathepsin D expression by cancer and stromal cells in breast cancer: an immunohistochemical study of 1348 cases, Breast Cancer Res Treat 55 (1999), 137-147.
134. B. Têtu, J. Brisson, C.S. Wang, H. Lapointe, G. Beaudry and C. Blanchette, Expression of cathepsin D, stromelysin-3, and urokinase by reactive stromal cells on breast carcinoma prognosis, Cancer 92 (2001), 2957-2964.
135. P.M. Ravdin, A.K. Tandon, D.C. Allred, G.M. Clark, S.A. Fuqua, S.H. Hilsenbeck, G.C. Chamness and C.K.Osborne, Cathepsin D by western blotting and immunohistochem-istry: failure to confirm correlations with prognosis in node-negative breast cancer, J Clin Oncol 12 (1994), 467-474.
136. O.A. Armas, W.L. Gerald, M.L. Lesser, C.D. Arroyo, L. Norton and P.P. Rosen, Immunohistochemical detection of cathepsin D in T2N0M0 breast carcinoma, Am J Surg Pathol 18 (1994), 158-166.
137. P.M. Ravdin, C.A. de Moor, S.G. Hilsenbeck, M.K. Samoszuk, P.M. Vendely and G.M. Clark, Lack of prognostic value of cathepsin D levels for predicting short term outcomes ofbreast cancer patients, Cancer Lett 116 (1997), 177-183.
138. E. Niskanen, C. Blomqvist, K. Franssila, P. Hietanen and V.M. Wasenius, Predictive value of c-erbB-2, p53, cathepsin-D and histology of the primary tumour in metastatic breast cancer, Br J Cancer 76 (1997), 917-922.
139. M, Jagodic, I, Vrhovec, S. Borstnar and T. Cufer, Prognostic and predictive value of cathepsins D and L in operable breast cancer patients, Neoplasma 52 (2005), 1-9.
140. P. Glikman, A. Rogozinski, J. Mosto, A. Pollina, C. Gar-bovesky and C. Levy, Relationship between cathepsin-D and other prognostic factors in human breast cancer, Tumori 83 (1997), 685-688.
141. N. Harbeck, P. Dettmar, C. Thomssen, B. Henselmann, W. Kuhn, K. Ulm, F. Jänicke, H. Höfler, H. Graeffand and M. Schmitt, Prognostic impact of tumor biological factors on survival in node-negative breast cancer, Anticancer Res 18 (1998), 2187-2197.
142. G. Ferrandina, G. Scambia, F. Bardelli, P. Benedetti Panici, S. Mancuso and A. Messori, Relationship between cathepsin-D content and disease-free survival in node-negative breast cancer patients: a meta-analysis, Br J Cancer 76 (1997) 661-666.
143. N.Bossard, F.Descotes, A.G. Bremond, Y.Bobin, P.DeSaint Hilaire, F. Golfier, A. Awada, P.M. Mathevet, L. Berrerd, Y. Barbier and J. Estève, Keeping data continuous when analyzing the prognostic impact of a tumor marker: an example with cathepsin D in breast cancer, Breast Cancer Res Treat 82 (2003), 47-59.
144. L. Harris, H. Fritsche, R. Mennel, L. Norton, P. Ravdin, S. Taube, M.R. Somerfield, D.F. Hayes and R.C. Jr. Bast, American Society of Clinical Oncology, update of recommendations for the use of tumor markers in breast cancer, J Clin Oncol 25 (2007), 5287-5312. (Pubitemid 350232263)
145. H. Allgayer, R. Babic, K.U. Grützner, B.C. Beyer, A. Tara-bichi, F. Wilhelm Schildberg and M.M. Heiss, An immuno-histochemical assessment of cathepsin D in gastric carcinoma: its impact on clinical prognosis, Cancer 80 (1997), 179-187.
146. H. Allgayer, R. Babic, K.U. Grützner, B.C. Beyer, A. Tara-bichi, F.W. Schildberg and M.M. Heiss, Tumor-associated proteases and inhibitors in gastric cancer: analysis of prognostic impact and individual risk protease patterns, Clin Exp Metastasis 16 (1998), 62-73.
147. M. Ikeguchi, K. Fukuda, S. Oka, K. Yamaguchi, K. Hisamit-su, S. Tsujitani, T.Sakatani, T.Ueda and N. Kaibara, Clinico-pathological significance of cathepsin D expression in gastric adenocarcinoma, Oncology 61 (2001), 71-78. (Pubitemid 32727591)
148. K. Matsuo, I. Kobayashi, T. Tsukuba, T. Kiyoshima, Y. Ishibashi, A. Miyoshi, K. Yamamoto and H. Sakai, Immuno-histochemical localization of cathepsins D and E in human gastric cancer: a possible correlation with local invasive and metastatic activities of carcinoma cells, Hum Pathol 27 (1996), 184-190.
149. G.E. Theodoropoulos, A.C. Lazaris, D. Panoussopoulos, P. Davaris and B.C. Golematis, Significance of estrogen receptors and cathepsin D tissue detection in gastric adenocarci-noma, J Surg Oncol 58 (1995), 176-183.
150. A. Russo, V. Bazan, M. Migliavacca, I. Zanna, C. Tubiolo, F.M. Tumminello, G. Dardanoni, M. Cajozzo, P. Bazan, G. Modica, M. Latteri, R.M. Tomasino, G. Colucci, N. Gebbia and G. Leto, Prognostic significance of DNA ploidy, S-phase fraction, and tissuelevels of aspartic, cysteine, and serine proteases in operable gastric carcinoma, Clin Cancer Res 6 (2000), 178-184.
151. J. Manuel Del Casar, F.J. Vizoso, O. Abdel-Laa, L. Sanz, A. Mart́in, M. D. Corte, M. Bongera, J.L. Garćia Muñiz and A. Fueyo, Prognostic value of cytosolyc cathepsin D content in resectable gastric cancer, J Surg Oncol 86 (2004), 16-21.
152. B. Nakata, HE. Appert and SZ. Lei, Immunohistochemical study on cathepsin B and D in pancreatic cancer, Oncol Rep 1 (1994), 543-546.
153. M. Niedergethmann, R. Hildenbrand, G. Wolf, C.S. Verbeke, A. Richter and S. Post, Angiogenesis and cathepsin expression are prognostic factors in pancreatic adenocarcinoma after curative resection, Int J Pancreatol 28 (2000), 31-39.
154. J. Shen, M.D. Person, J. Zhu, J.L. Abbruzzese and D. Li, Protein expression profiles in pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as detected by two-dimensional gel electrophore-sis and mass spectrometry, Cancer Res 64 (2004), 9018-9026.
155. R. Chen, T.A. Brentnall, S. Pan, K. Cooke, K.W. Moyes, Z. Lane, D.A. Crispin, D.R. Goodlett, R. Aebersold and M.P. Bronner, Quantitative proteomics analysis reveals that proteins differentially expressed in chronic pancreatitis are also frequently involved in pancreatic cancer, Mol Cell Proteomics 6 (2007), 1331-1342.
156. G. Leto, F.M. Tumminello, G. Pizzolanti, G. Montalto, M. Soresi, I. Ruggeri and N. Gebbia Cathepsin D serum mass concentrations in patients with hepatocellular carcinoma and/or liver cirrhosis, Eur J Clin Chem Clin Biochem 34 (1996), 555-560.
157. A. Adenis, G. Huet, F. Zerimech, B. Hecquet, M. Balduyck and J.P. Peyrat, Cathepsin B,L, and D activities in colorectal carcinomas: relationship with clinico-pathological parameters, Cancer Lett 96 (1995), 267-275.
158. R.M. Shaheen, S. Miseljic, D.L. Doering and J.L. Wittliff, Comparison of cathepsin D determinations in human carcinomas by enzyme immunoassay and immunoradiometric assay, J Clin Lab Anal 9 (1995), 351-358.
159. R. Holm and G. Tanum, Evaluation of the prognostic significance of nm23/NDP kinase and cathepsin D in anal carcinomas. An immunohistochemical study, Virchows Arch 428 (1996), 85-89.
160. M.L. Caruso and A.M. Valentini, Immunohistochemical p53 overexpression correlated to c-erbB-2 and cathepsin D proteins in colorectal cancer, Anticancer Res 16 (1996), 3813-3818.
161. A.M. Valentini, M. Pirrelli, R. Armentano and M.L. Caruso, The immunohistochemical expression of cathepsin D in colorectal cancer, Anticancer Res 16 (1996), 77-80.
162. A. Mayer, E. Fritz, R. Fortelny, K. Kofler and H. Ludwig, Immunohistochemical evaluation of cathepsin D expression in colorectal cancer, Cancer Invest 15 (1997), 106-110.
163. G.E. Theodoropoulos, D. Panoussopoulos, A.C. Lazaris and B.C. Golematis, Evaluation of cathepsin D immunostaining in colorectal adenocarcinoma, J Surg Oncol 65 (1997), 242-248.
164. E. Ioachim, A. Goussia and N.J. Agnantis, Glycoprotein CD44 expression in colorectal neoplasms. An immuno-histochemical study including correlation with cathepsin D, extracellular matrix components, p53, Rb, bcl-2, c-erbB-2, EGFR and proliferation indices, Virchows Arch 434 (1999), 45-50.
165. B. Zalewski, W. Famulski, M. Sulkowska, M. Sobaniec-Lotowska, Z. Piotrowski, W. Kisielewski and S. Sulkows-ki, CD44 expression in colorectal cancer. An immunohisto-chemical study including correlation with cathepsin D im-munoreactivity and some tumour clinicopathological features, Folia Histochem Cytobiol 2 (2001), 152-153.
166. W. Famulski, K. Guzińska-Ustymowicz, M. Sulkowska, A. Chabowski, B. Zalewski, Z. Piotrowski, A. Stasiak-Barmuta and S. Sulkowski, Tumour budding intensity in relation to cathepsin D expression and some clinicopathological features of colorectal cancer, Folia Histochem Cytobiol 2 (2001) 171-172.
167. Y. Kanber, N.R. Demirbag, A.D. Sam and N. Aydin, Cathep-sin D expression in colorectal adenocarcinomas and adenomas, Int J Biol Markers 17 (2002), 165-168.
168. B. Sis, O. Sag?ol, A. Küpeliog?lu, S. Sokmen, C. Terzi, M. Fuzun, E. Ozer and P. Bishop, Prognostic significance of matrix metalloproteinase-2, cathepsin D,and tenascin-C expression in colorectal carcinoma, Pathol Res Pract 200 (2004) 379-387.
169. E. Skrzydlewska, M. Sulkowska, A. Wincewicz, M. Koda and S. Sulkowski, Evaluation of serum cathepsin B and D in relation to clinicopathological staging of colorectal cancer, World J Gastroenterol 11 (2005), 4225-4229.
170. I. Kaneko, S. Tanaka, S. Oka, S. Yoshida, T. Hiyama, K. Arihiro, F. Shimamoto and K. Chayama, Immunohistochem-ical molecular markers as predictors of curability of endo-scopically resected submucosal colorectal cancer, World J Gastroenterol 13 (2007), 3829-3835.
171. Y. Yang, G.D. Chisholm and F.K. Habib, The distribution of PSA, cathepsin-D, and pS2in BPH and cancer of the prostate, Prostate 21 (1992), 201-208.
172. M. Chambon, X. Rebillard, H. Rochefort, J.P. Brouillet, P. Baldet and J. Guiter, T. Maudelonde. Cathepsin D cytoso-lic assay and immunohistochemical quantification in human prostate tumors, Prostate 24 (1994), 320-325.
173. R. Makar, A. Mason, J.M. Kittelson and G.T. Bowden, A.E. Cress, R.B. Nagle. Immunohistochemical analysis of cathep-sin D in prostate carcinoma, Mod Pathol 7 (1994), 747-751.
174. J.S. Ross, T. Nazeer, H.L. Figge, H.A. Fisher and M.D. Rifkin, Quantitative immunohistochemical determination of cathepsin D levels in prostatic carcinoma biopsies. Correlation with tumor grade, stage, PSA level, and DNA ploidy status, Am J Clin Pathol 104 (1995), 36-41.
175. J.W. Moul, S.J. Maygarden, J.L. Ware, J.L. Mohler, P.D. Ma-her, N.S. Schenkman and C.K. Ho, Cathepsin D and epidermal growth factor receptor immunohistochemistry does not predict recurrence of prostate cancer in patients undergoing radical prostatectomy, J Urol 155 (1996), 982-985.
176. D. Theodorescu, S.R. Broder, J.C. Boyd, S.E. Mills and H.F. Jr. Frierson, CathepsinD and chromogranin A aspredictors of longterm disease specific survivalafter radical prostatectomy for localized carcinoma of the prostate, Cancer 80 (1997), 2109-2119.
177. J.P. Cherry, J.A. Mordente, J.R. Chapman, M.S. Choudhury, H. Tazaki, C. Mallouh and S. Konno, Analysis of cathepsin D forms and their clinical implications in human prostate cancer, J Urol 160 (1998), 2223-2228.
178. J.A. Mordente, M.S. Choudhury, H. Tazaki, C. Mallouh and S. Konno, Hydrolysis of androgen receptor by cathepsin D: its biological significance inhuman prostate cancer, Br JUrol 82 (1998), 431-435.
179. H. Miyake, I. Hara and H. Eto, Prediction of the extent of prostate cancer by the combined use of systematic biopsy and serum level of cathepsin D, Int J Urol 10 (2003), 196-200.
180. I. Hara, H. Miyake, K. Yamanaka, S. Hara and S. Kamidono, Serum cathepsinD and its densityinmen with prostate cancer as new predictors of disease progression, Oncol Rep9(2002), 1379-1383.
181. S.C. Henzen-Logmans, E.J. Fieret, E.M. Berns, M.E. van der Burg, J.G. Klijn and J.A. Foekens, Ki-67 staining in benign, borderline, malignant primary and metastatic ovarian tumors: correlation with steroid receptors, epidermal-growth-factor receptor and cathepsin D, Int J Cancer 57 (1994), 468-472.
182. G. Scambia, P. Benedetti, G. Ferrandina, F. Battaglia, G. Baiocchi and S. Mancuso, Cathepsin D assay in ovarian cancer: correlation with pathological features and receptors for oestrogen, progesterone and epidermal growth factor, Br J Cancer 64 (1991), 182-184.
183. G. Scambia, P.B. Panici, G. Ferrandina, G. Salerno, G. D'Agostino, M. Distefano, R. de Vincenzo, A. Ercoli and S. Mancuso, Clinical significance of cathepsin D in primary ovarian cancer, Eur J Cancer 30 (1994), 935-940.
184. M. Kaufmann, G. Von Minckwitz, W. Kühn, H. Schmid, S. Costa, K. Goerttler and G. Bastert, Combination of new biologic parameters as a prognostic index inepithelialovarian carcinoma, Int J Gynecol Cancer 5 (1995), 49-55.
185. C. Tecimer, D.L. Doering, L.J. Goldsmith, J.S. Meyer, G. Abdulhay and J.L. Wittliff, Clinical relevance of urokinase-type plasminogen activator, its receptor and inhibitor type 1 in ovarian cancer, Int J Gynecol Cancer 10 (2000), 372-381.
186. A. Protopapas, E. Diakomanolis, A. Bamias, S. Milingos, S. Markaki, C. Papadimitriou, A.M. Dimopoulos and S. Micha-las, The prognostic significance of the immunohistochemi-cal expression of p53, bcl-2, c-erb B-2 and cathepsin-D in ovarian cancer patients receiving platinum with cyclophos-phamide or paclitaxel chemotherapy, Eur J Gynaecol Oncol 25 (2004), 225-229.
187. M. Baekelandt, R. Holm, C.G. Tropé, J.M. Nesland and G.B. Kristensen, The significance of metastasis-related factors cathepsin-D and nm23 in advanced ovarian cancer, Ann Oncol 10 (1999), 1335-1341.
188. P. Athanassiadou, V. Sakellariou, E. Petrakakou, P. Athanas-siades, C. Zerva, A. Liossi and S. Michalas, Cathepsin D im-munoreactivity in ovarian cancer: correlation withprognostic factors, Pathol Oncol Res 4 (1998), 103-107.
189. A. Lösch, M. Schindl, P. Kohlberger, J. Lahodny, G. Bre-itenecker, R. Horvat and P. Birner, Cathepsin D in ovarian cancer: prognostic value and correlation with p53 expression and microvessel density, Gynecol Oncol 92 (2004), 545-552.
190. T. Salman, O. el-Ahmady, M. el-Shafee, S. Omar and I. Salman, Cathepsin-D and TNF-alpha in bladder cancer, Dis Markers 121 (1996), 253-259.
191. E. Ozer, M.U. Mungan, B. Tuna, H. Kazimog?lu, K. Yörükog?lu and Z Kirkali, Prognostic significance of angio-genesis and immunoreactivityof cathepsinD and type IV collagen in high-grade stage T1primary bladdercancer, Urology 54 (1999), 50-55.
192. C. Carrascosa Lloret, A. Cremades Mira, M. Sánchez San-chis, V. Rodrigo Guanter, JR. Beltrán Armada, A. Sala Aznar, R. Vacacela Córdova, B. CoronelSánchez, F. Clar Blanch, M. Tarin Planes and C. Sanjuán de Laorden, Study of cathepsin D levels ininvasive bladder cancer andits stroma. Correlation with tumor stage, cytological grade, lymph node metastasis and survival, Actas Urol Esp 26 (2002), 335-338.
193. A.J. Dickinson, S.B. Fox, P.V. Newcomb, R.A. Persad, G.N. Sibley and A.L. Harris, An immunohistochemical and prognostic evaluation of cathepsin D expression in 105 bladder carcinomas, J Urol 154 (1995), 237-241.
194. T. Iizumi, T. Iiyama, W. Tanaka, E. Okada, Y. Kamiyama, Y. Okano, S. Sato, T. Yazaki, T. Umeda and T. Imamura, Immunohistochemical studies of proliferating cell nuclear antigen and cathepsin D in transitional cell carcinoma of the urinary bladder, Urol Int 59 (1997), 81-87.
195. C. Tokyol, T. Köken, M. Demirbas, F.H. Dilek, K. Yörükoglu, U. Mungan and Z. Kirkali, Expression of cathep-sin D in bladder carcinoma: correlation with pathological features and serum cystatin C levels, Tumori 92 (2006), 230-235.
196. E. Ioachim, A. Charchanti, N. Stavropoulos, E. Athanassiou, M. Bafa and N.J. Agnantis, Expression of cathepsin D in urothelial carcinoma of the urinary bladder: an immuno-histochemical study including correlations with extracellular matrix components, CD44, p53, Rb, c-erbB-2 and the proliferation indices, Anticancer Res 22 (2002), 3383-3388.
197. P.Gontero, S. Banisadr, B. Frea and M. Brausi, Metastasis markers in bladder cancer:a review of the literature and clinical considerations, Eur Urol 46 (2004), 296-311.
198. O.L. Podhajcer, L. Bover, A.I. Bravo, M.F. Ledda, C. Kairiya-ma, I. Calb, L. Guerra, F. Capony and J. Mordoh, Expression of cathepsin D in primary and metastatic human melanoma and dysplastic nevi, J Invest Dermatol 104 (1995), 340-344.
199. T. Kageshita, A. Yoshii, T. Kimura, K. Maruo, T. Ono, M. Himeno and Y. Nishimura, Biochemical and immunohisto-chemical analysis of cathepsins B, H, L and D in human melanocytic tumours, Arch Dermatol Res 287 (1995), 266-272.
200. I. Bartenjev, Z. Rudolf, B. Stabuc, I. Vrhovec, T. Perkovic and A. Kansky, Cathepsin D expression in early cutaneous malignant melanoma, Int J Dermatol 39 (2000), 599-602.
201. F.J. Otto, T. Goldmann, B. Biess, A. Lippold, L. Suter and U. Westhoff, Prognostic classification of malignant melanomas by combining clinical, histological, and immunohistochem-ical parameters, Oncology 56 (1999), 208-214.
202. T. Goldmann, L. Suter, D. Ribbert and F. Otto, The expression of proteolytic enzymes at the dermal invading front of primary cutaneous melanoma predicts metastasis, Pathol Res Pract 195 (1999), 171-175.
203. U. Westhoff, C. Fox and F.J. Otto, Quantification of cathep-sin D in plasma of patients with malignant melanoma, Anti-cancer Res 18 (1998), 3785-3788. (Pubitemid 28564266)
204. M. Démoz, R. Castino, A. Dragonetti, E. Raiteri, F.M. Bac-cino and C. Isidoro, Transformation by oncogenic ras-p21 alters the processing and subcellular localization of the lyso-somal protease cathepsin D, J Cell Biochem 73 (1999), 370-378.
205. G. Nicotra, F. Manfroi, C. Follo, R. Castino, N. Fusco, C. Peracchio, S. Kerim, G. Valente and C. Isidoro, High expression of Cathepsin D in Non Hodgkin's Lymphomas negatively impacts on clinical outcome, Disease Markers (2010), (in press).